Market closedNon-fractional

Spruce Biosciences/SPRB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Spruce Biosciences

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Ticker

SPRB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

22

SPRB Metrics

BasicAdvanced
$24M
Market cap
-
P/E ratio
-$1.15
EPS
2.50
Beta
-
Dividend rate
$24M
2.5
4.668
4.412
3.409
6.232
-114.54%
-28.36%
-53.55%
2.304
0.35
0.35
-0.64
415.63%
-37.80%
-27.02%

What the Analysts think about SPRB

Analyst Ratings

Majority rating from 7 analysts.
Hold

SPRB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-580.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2M
-28.57%
Net income
-$12M
17.17%
Profit margin
-580.00%
64.04%

SPRB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.21%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.30
-$0.24
-$0.28
-
Expected
-$0.39
-$0.35
-$0.39
-$0.29
-$0.33
Surprise
-18.44%
-15.09%
-37.85%
-3.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Spruce Biosciences stock?

Spruce Biosciences (SPRB) has a market cap of $24M as of July 06, 2024.

What is the P/E ratio for Spruce Biosciences stock?

The price to earnings (P/E) ratio for Spruce Biosciences (SPRB) stock is 0 as of July 06, 2024.

Does Spruce Biosciences stock pay dividends?

No, Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Spruce Biosciences dividend payment date?

Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders.

What is the beta indicator for Spruce Biosciences?

Spruce Biosciences (SPRB) has a beta rating of 2.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Spruce Biosciences stock

Buy or sell Spruce Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing